Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Trial details
- Registry ID
- NCT04971109
- Phase
- Phase 3
The FDA approved TPOXX (tecovirimat) on 13 Jul 2018.
Drug identity checked against registry records
Also recorded as tecovirimat
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysNCT04971109 | SIGA Technologies | Phase 3 | Completed | 2023-05-12Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-07-13Day | TPOXX | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208627", "applicant_as_listed_by_fda": "SIGA TECHNOLOGIES", "brand_names": ["TPOXX"], "active_ingredients": ["TECOVIRIMAT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180713", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |